UNITED STATES PATENT AND TRADEMARK OFFICE					
BEFORE THE PATENT TRIAL AND APPEAL BOARD					
ITM Isotope Technologies Munich SE Petitioner					
v.					
The Johns Hopkins University Patent Owner					
Case PGR2025-00012 Patent No. 11,938,201					

EXPERT DECLARATION OF STEPHEN F. MARTIN, PH.D.

I declare that all statements made herein of my knowledge are true, that all statements made herein on information and belief are believed to be true, and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code.

By: Date: December 24, 2024

TABLE OF CONTENTS


I.	INTRODUCTION							
	A.	Experience and Qualifications						
	B.	Review and Use of Documents and Other Materials 4						
II.	SUM	MARY OF MY OPINIONS5						
III.	LEG	AL PRINCIPLES6						
IV.	TECHNOLOGY BACKGROUND9							
	A.	FAP Inhibitors9						
	B.	Optical and Radioimaging Agents12						
	C.	Prior Art References	16					
		1. Dvořáková	16					
		2. Jansen I	19					
		3. Zimmerman	22					
		4. Jansen II	26					
		5. Pomper	27					
V.	U.S. PATENT NO. 11,938,2012							
	A.	Specification29						
	B.	Prosecution History37						
	C.	Claims of the '201 Patent						
VI.	PER	SON OF ORDINARY SKILL IN THE ART	51					
VII.	CLAIM CONSTRUCTION							
	A.	"Low molecular weight"53						
	B.	"C(O)Alkyl" / "Aryl"57						



VIII.	INVALIDITY				
	A.	Ground I: Claims 1-3 Would Have Been Obvious to a POSA In View of Jansen I and/or Jansen II, Taken in View of Zimmerman and Pomper			
		1.	Clain	n 1	60
		2.	Clain	n 2	70
		3.	Clain	n 3	70
		4.	No S	econdary Indicia	71
	В.			Claims 1-3 Would Have Been Obvious to a POSA Dvořáková and Pomper	73
		1.	Clain	n 1	75
			a.	[1a] "A low molecular weight compound of Formula (I): B-L-A (I) wherein:"	75
			b.	[1b] "A is a targeting moiety for FAP-α, wherein A has the structure of"	75
			c.	[1c] "B is any optical or radiolabeled functional group suitable for optical imaging, positron-emission tomography (PET) imaging, single-photon emission computed tomography (SPECT) imaging, or radiotherapy"	79
			d.	[1d] "L is a linker having bi-functionalization adapted to form a chemical bond with B and A"	81
			e.	[1e] "or a stereoisomer, tautomer, racemate, salt, hydrate, or solvate thereof"	82
		2.	Clain	n 2	82
		3.	Clain	n 3	83
	C.	Grou	nd III:	Claims 1-3 Lack of Enablement	84
		1.	Scope	e of the Claimed Invention	84



		2.	Existence of Specific Working Examples	87	
		3.	Guidance in the Specification	89	
		4.	Level of Ordinary Skill in the Art	90	
		5.	Nature and Predictability of the Art	91	
		6.	Quantity of Experimentation Needed	92	
		7.	How Routine Any Necessary Experimentation Is in the Relevant Field	93	
		8.	Weighing the Wands Factors	93	
	D.	Ground IV: Claims 1-3 Lack Written Description			
	E.	Ground V: Claims 1-3 are Indefinite			
IV	CON		SION	100	



I. INTRODUCTION

- 1. I have been retained by counsel for Petitioner ITM Isotope Technologies Munich SE ("Petitioner") as an independent expert consultant in this proceeding before the U.S. Patent and Trademark Office ("USPTO"). I am being compensated for the time I spend on this matter, but no part of my compensation is dependent on the outcome of this proceeding.
- 2. I understand that this proceeding involves U.S. Patent No. 11,938,201 ("the '201 patent"), issued on March 26, 2024. EX1001 at Cover. I understand that the application for the '201 patent was filed on July 18, 2023, as U.S. Patent Application No. 18/354,282, and claims a priority date of October 23, 2017. *Id*.
- 3. I submit this Declaration on behalf of Petitioner as an expert in the field of organic chemistry, including bioactive natural products and molecular probes, in the above-identified proceeding. My qualifications in these areas, as well as other areas, are established below and by my *curriculum vitae* (EX1003).

A. Experience and Qualifications

4. I received a B.S. degree in chemistry from the University of New Mexico in 1968 and a Ph.D. degree in chemistry from Princeton University in 1972. After postdoctoral years at the University of Munich and Massachusetts Institute of Technology, I joined the faculty at The University of Texas at Austin (UTA) in 1974



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

